Comparable stake leader
Decheng Capital Global Life Sciences Fund IV, L.P.
SEC ownership of Aardvark Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001774857.
Disclosed value leader
Tien-Li Lee
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- AARD on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Decheng Capital Global Life Sciences Fund IV, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Decheng Capital Global Life Sciences Fund IV, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001774857
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Aardvark Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Decheng Capital Global Li...
Disclosed value leader
Tien-Li Lee
Comparable rows
50/50
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 18%
13D/G row: Decheng Capital Global Life Sciences Fund IV, L.P.
Showing 1-8 of 50 holder rows.
Quick read
Decheng Capital Global Life Sciences Fund IV, L.P. leads the comparable SEC ownership view at 18%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Decheng Capital Global Life Sciences Fund IV, L.P.'s linked filing trail.
Comparable ownership
Top 5
Decheng Capital Global Life Scien...
18%
Tien-Li Lee
14%
Finian Tan
9.6%
CITADEL ADVISORS LLC
5.6%
Decheng Capital LLC
18%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. |
3/4/5
13D/G
10%+ Owner · Xiangmin Cui
|
18%
from 13D/G
|
—
3,917,299 shares
|
— | 14 Feb 2025 |
| Tien-Li Lee |
3/4/5
13D/G
Chief Executive Officer, Director, 10%+ Owner
|
14%
from 13D/G
|
$38,483,058
3,229,492 shares
mixed-class rows
|
+$101,395 | 09 Feb 2026 |
| Finian Tan |
13D/G
Vickers Venture Fund VI Pte. Ltd.
|
9.6%
|
$23,441,810
2,050,902 shares
|
$0 | 12 Feb 2025 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
5.6%
|
$13,635,659
1,192,971 shares
|
$0 | 14 Feb 2025 |
| Decheng Capital LLC |
13F
Company
|
18%
|
$22,563,642
3,917,299 shares
|
— | 30 Jun 2026 |
| Laurion Capital Management LP |
13F
Company
|
4.9%
|
$5,958,484
1,034,459 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
2.6%
|
$3,242,172
562,877 shares
|
— | 30 Jun 2026 |
| AQR CAPITAL MANAGEMENT LLC |
13F
Company
|
2.3%
|
$2,766,234
480,249 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$250,362.
Buys
$144,595
Insiders: 2
Sells
$394,957
Insiders: 1
Net
-$250,362
Shares: -66,754
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 10,000
Shares: 76,754
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 76,754 | $0 | $394,957 | -$394,957 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 10,000 | 0 | $144,595 | $0 | +$144,595 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Aardvark Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Tien-Li Lee
Net 12M change
-$250,362
Latest report
10 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Tien-Li Lee | Chief Executive Officer, Director, 10%+ Owner | $38,483,058 | +$101,395 | +0.26% | Mixed | 09 Feb 2026 |
| Nelson Sun | Chief Financial & Operating Officer | $183,771 | -$351,757 | -66% | Filing P/S | 10 Sep 2026 |
| Bryan Jones | Chief Operating Officer | $5,300 | Mixed | 15 Oct 2025 | ||
| Jeffrey Chi | Director | Mixed | 14 Aug 2026 | |||
| Susan E. Graf | Director | Mixed | 14 Aug 2026 | |||
| Roy D. Baynes | Director | Mixed | 14 Aug 2026 | |||
| Victor Edward Tong Jr. | Director | Mixed | 14 Aug 2026 | |||
| Manasi Jaiman | Chief Medical Officer | Mixed | 09 Feb 2026 | |||
| Vickers Venture Fund VI Pte Ltd | 10%+ Owner | Mixed | 14 Feb 2025 | |||
| Decheng Capital Global Life Sciences Fund IV, L.P. | 10%+ Owner | Mixed | 14 Feb 2025 | |||
| Cormorant Asset Management, LP | Former 10% Owner | Mixed | 14 Feb 2025 |
Recent insider transactions for Aardvark Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Nelson Sun | AARD | Common Stock, par value $0.00001 per share | Sale | -63.6% | $321,179 | $5.18 | -62,000 | 35,475 | 11 Sep 2026 | Direct |
| Nelson Sun | AARD | Common Stock, par value $0.00001 per share | Sale | -13.2% | $73,779 | $5.00 | -14,754 | 97,475 | 10 Sep 2026 | Direct |
| Jeffrey Chi | AARD | Stock Option (right to buy) | Award | 44,964 | 44,964 | 14 Aug 2026 | Direct | |||
| Susan E. Graf | AARD | Stock Option (right to buy) | Award | 44,964 | 44,964 | 14 Aug 2026 | Direct | |||
| Roy D. Baynes | AARD | Stock Option (right to buy) | Award | 44,964 | 44,964 | 14 Aug 2026 | Direct | |||
| Victor Edward Tong Jr. | AARD | Stock Option (right to buy) | Award | 44,964 | 44,964 | 14 Aug 2026 | Direct | |||
| Nelson Sun | AARD | Stock option (right to buy) | Award | -50% | -70,549 | 70,549 | 09 Feb 2026 | Direct | ||
| Manasi Jaiman | AARD | Stock option (right to buy) | Award | -50% | -70,549 | 70,549 | 09 Feb 2026 | Direct | ||
| Tien-Li Lee | AARD | Stock option (right to buy) | Award | -50% | -203,851 | 203,851 | 09 Feb 2026 | Direct | ||
| Nelson Sun | AARD | Common Stock | Purchase | 2.84% | $43,200 | $14.40 | 3,000 | 108,484 | 11 Dec 2025 | Direct |
| Tien-Li Lee | AARD | Common Stock | Purchase | 0.45% | $101,395 | $14.48 | 7,000 | 1,551,613 | 11 Dec 2025 | Direct |
| Tien-Li Lee | AARD | Common Stock | Options Exercise | 0.08% | 1,229 | 1,544,613 | 15 Oct 2025 | Direct | ||
| Tien-Li Lee | AARD | Stock option (right to buy) | Options Exercise | -2.94% | -1,229 | 40,566 | 15 Oct 2025 | Direct | ||
| Bryan Jones | AARD | Common Stock | Options Exercise | 1,250 | 1,250 | 15 Oct 2025 | Direct | |||
| Bryan Jones | AARD | Stock option (right to buy) | Options Exercise | -3.03% | -1,250 | 40,052 | 15 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.